Comparison of long-term safety of the combination product QVA149A against placebo and standard of care treatment in Chronic Obstructive Pulmonary Disease patients with moderate to severe airflow limitation To demonstrate the non-inferiority of QVA149 110/50 μg qd compared to placebo in terms of overall SAE rate from initiation of study treatment through 30 days post last treatment.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Essai de phase 3 randomisé, en double aveugle évaluant l’efficacité et la tolérance d’un traitement comprenant du bortézomib et de la dexaméthasone associé ou non à du panobinostat, chez des patients ayant un myélome multiple en rechute. [essai clos aux inclusions] L’objectif de cet essai est de déterminer si l’association de panobinostat, du bortézomib (velcade®) et de la dexaméthasone est bien tolérée et a une activité anti-myélomateuse plus efficace que l’ass...

• Pays France
• Organes Myélomes
• Spécialités Chimiothérapie, Thérapies Ciblées

Dovigist : Phase II trial to evaluate the treatment benefits and the safety of the new investigational medicine Dovitinib (TKI258) in patients with specific cancers in the gastrointestinal tract which do not respond any more to the currently established standard treatment imatinib or can not be treated any more with imatinib because of intolerance To assess the antitumor activity of Dovitinib (TKI258) in terms of disease control rate (DCR): CR+PR+SD, at 12 weeks in adult patients with documented disease progression while on therapy with imati...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A clinical study to evaluate the safety and benefit from using Everolimus and Exemestane in combination in postmenopausal women with estrogen receptor positive breast cancer To assess the Overall Response Rate (ORR) in postmenopausal women with hormone receptor positive breast cancer progressing following prior therapy with NSAIs treated with the combination of Everolimus...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis assessing different doses and dose regimens Efficacy of secukinumab over 52 weeks based on PASI, in two different doses and two treatment regimens (fixed interval vs personalized treatment), in subjects with moderate to severe chronic plaque-ty...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An 8 week, double-blind, randomized, parallel group, active-controlled study to evaluate the efficacy and safety of the combination of Aliskiren /Amlodipine / HCTZ in patients with moderate to severe hypertension The primary objective of the study is to demonstrate that a once daily dosing regimen of the triple combination of aliskiren/amlodipine/HCTZ is superior to the double combinations of aliskiren/amlodip...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized, double-blind, double-dummy, active controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares, for whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective The two co-primary objectives of this study are: • To confirm that canakinumab 150 mg s.c. is superior to triamcinolone acetonide 40 mg i.m. with respect to patient’s assessment of gout pain intensity...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy To determine the objective response rate (ORR) (including complete response and partial response) of RAD001 10 mg po qd monotherapy in patients with advanced (unresectable or metastatic) pancreatic NE...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study of everolimus plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced neuroendocrine cancer of gastrointestinal or lung origin. Klinické hodnocení everolimu plus nejlepší podpůrná léčba versus placebo plus nejlepší podpůrná léčba v léčbě pacientů s pokročilými neuroendokrinními nádory gastrointestinálního nebo plicního původu Determinate whether treatment with everolimus plus best supportive care prolongs PFS compared to placebo plus best supportive care in patients with advanced NET of GI or lung origin

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An interventional study of PDR001 in adult patients with nasopharyngeal carcinoma (NPC) who have progressed on standard treatment To assess the efficacy of PDR001 versus investigator’s choice of chemotherapy in patients with moderately differentiated / undifferentiated locally advanced recurrent or metastatic NPC who progressed...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune